Presentation Preview
Disruption to normal sleep/wake cycles results in substantial disability and loss of productivity. Sleep/wake cycle dysfunction can also increase morbidity and mortality and therefore remains an urgent target for the development of medicines that can ameliorate such dysfunction.
In the field of sleep medicine, the meaning of changes in cognition can be communicated using various terms such as fatigue, drowsiness, sleepiness, sedation, diminished alertness and diminished attention. Such variability reduces the ability of clinical teams to make decisions about the nature and magnitude of cognitive impairment in disorders of the sleep/wake cycle, the effects of sedative and alerting drugs in experimental medicine models and the best approach to utilize cognitive information in late-phase clinical trials.
In this webinar, Prof. Paul Maruff utilizes published cognitive test data obtained from many clinical trials and provide a framework for understanding the nature and magnitude of cognitive impairment that can occur in disorders of the sleep/wake cycle. Data are obtained from trials of patients with disrupted sleep/wake cycles, healthy adults who have received medicines with sedative effects and healthy adults who have undergone long periods of sleep restriction. This framework will help research teams make informed decisions about the safety and efficacy of sleep-related drug candidates.
Watch this webinar today to discover how data on cognition can provide insights into the cognitive impairment that may arise in sleep medicine drug development.
Speaker
Paul Maruff, PhD
Chief Innovation Officer, Cogstate
